Rad Quotes From RAD 2023
Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.
2023 Revolutionizing Atopic Dermatitis Recap
Catch up on all coverage from Revolutionizing Atopic Dermatitis.
Ruxolitinib Cream Provides Substantial, Sustained Itch Relief in AD Patients
A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.
Discussing Disparities in AD With Andrew Alexis, MD, MPH
Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”
Assessing Itch Severity and Skin Clearance Supports Shared Decision Making
New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.
Digital Educational Intervention Increases Awareness Among Hispanic Patients With AD
The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.
Dupilumab Efficacious in Pediatric Patients as Young as 6 Months
The drug was both safe and effective in patients ages 6 months to 5 years.
Crucial Conversations Are Needed to Address Racism in Medicine
Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.
Revolutionizing Atopic Dermatitis Recap: Day 3
Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.
Abrocitinib Has Acceptable Long-Term Safety Profile in Adolescents with AD
Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.
Late-Breaking Data: Dupilumab Significantly Improves Signs, Symptoms, and QoL in Patients With Hand & Foot Dermatitis
Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.
New Drugs in 2023, Patient Satisfaction, and RAD Takeaways With Melinda Gooderham, MSc, MD, FRCPC
Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.
Crisaborole Ointment Leads to Significant, Consistent Improvements in AD
In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.
Upadacitinib, Long-Term Control, and Tapinarof, Oh My!
Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.
Lebrikizumab Efficacious in Clearing Hand, Facial Atopic Dermatitis
In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.
Boxed Warnings Should Not Create a Fear of Using All JAK Inhibitors for AD
Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.
No Differences in Severity or Treatment Among Racially Diverse Eczema Patients
In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.
The Science of Atopic Dermatitis With Anna De Benedetto, MD
De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.
Revolutionizing Atopic Dermatitis Recap: Day 2
Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.
Christopher Bunick, MD, PhD, Discusses Late-Breaking Long-Term 4-Year Safety Data of Upadacitinib for AD
Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.
Using Biologic Treatments in Atopic Dermatitis
Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."
Determining Systemic Therapy Eligibility in Patients With Atopic Dermatitis
Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"
FFPE-Based Molecular Classifier Precisely Separates Eczema From Psoriasis
A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.
Previewing Dermatology Times Editorial Advisory Board Member Sessions at RAD 2023
Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.
Revolutionizing Atopic Dermatitis Recap: Day 1
Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.
What to Look Forward to at RAD 2023
Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.
Previewing RAD 2023 With Raj Chovatiya, MD, PhD
The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.
Plan Your Trip: What to do While Visiting Washington, DC
When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.
What to Expect at the 2023 Revolutionizing Atopic Dermatitis Conference
The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.
POLL: What Topics Do You Want to See Us Cover at RAD?
Let us know what content you want to see from RAD.
2 Clarke Drive Cranbury, NJ 08512